|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.7 TWD | +0.25% |
|
+5.17% | -37.48% |
| 05-28 | Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index | CI |
| 05-13 | Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Tanvex BioPharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 22.4 million compared to TWD 5.41 million a year ago. Net loss was TWD 1,641.13 million compared to TWD 1,543.21 million a year ago.
Basic loss per share from continuing operations was TWD 13.9398 compared to TWD 14.2096 a year ago. Diluted loss per share from continuing operations was TWD 13.9398 compared to TWD 14.2096 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -37.48% | 207M | |
| +19.33% | 125B | |
| +13.95% | 108B | |
| -3.53% | 24.57B | |
| +3.87% | 22.82B | |
| -11.07% | 18.19B | |
| -41.48% | 16.54B | |
| -12.62% | 16.5B | |
| +0.99% | 13.39B | |
| +21.79% | 11.1B |
TANVEX BIOPHARMA, INC. 
